Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alternating therapy.

Trial Details

NCT ID
NCT07142551
Phase
PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Testosterone cypionate
  • Luteinizing hormone-releasing hormone (LHRH) analogue
  • Darolutamide
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Age ≥ 18 years
  • Performance status ≤2.
  • Documented histologically confirmed adenocarcinoma of the prostate.
  • Baseline PSA ≥1.0 ng/ml.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →